2014 is coming to a miserable close for Chapel Hill-based Pozen.

After its stock was pummeled 30 percent when Pozen and drug giant Sanofi mutually terminated a $35 million drug deal earlier this month, on Wednesday Pozen disclosed another FDA delay in approval of a new pain killer.

The news sent shares down more than 10 percent, closing at $8.10. they at one point traded as low as $7.62.

The receipt of a second delay from the Food and Drug Administration regarding concerns about production of the proposed Yosprala product, Pozen (Nasdaq: POZN) Chairman and CEO John Plachetka was left frustrated by the news.

“Based on inspections at the site by an expert consultant we retained and our review of all relevant documents and communications with the supplier’s personnel, we believe that the FDA issues raised during the April inspection have been adequately addressed,” Plachetka said.

“So, our goal continues to be to do everything we can to assist the FDA compliance division with their review and to encourage them to move to completion of their review as soon as possible since this remains the only outstanding issue.”

But Pozen is not giving up.

“FDA regulations allow us to request a Type A meeting with the FDA to discuss the next steps required to gain approval of our NDA and we intend to request that meeting as soon as possible,” Plachetka said.

NDA is a new drug application.

In July, the FDA accepted Pozen’s new drug application after concerns about production problems were addressed.

Pozen’s statement at that time:

“POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review, the resubmission of the New Drug Application (NDA) for PA8140/PA32540. The FDA also indicated the NDA would be treated as a Class 2 resubmission; therefore, the new user fee goal date is December 30, 2014. Issues raised during an audit of the manufacturing facility producing an active ingredient used in the manufacture of the products were the only deficiencies noted in the Complete Response Letter (CRL) POZEN received on April 25, 2014. If such inspection deficiencies are not satisfactorily addressed by the new user fee goal date, the FDA could issue another CRL. POZEN has agreed substantively to FDA’s most recent draft product labeling.”